

Each drug is recommended for use in combination with other antiretrovirals (except any single-tablet regimen, including Atripla, Biktarvy, Complera, Delstrigo, Genvoya, Juluca, Odefsey, Stribild, Symfi, Śymfi Lo, Symtuza, and Triumeq). For a complete description of DHHS drug recommendations, go to aidsinfo.nih.gov/guidelines. Consult with a physician about which drug therapy and dose is appropriate for you; see drug page or package insert for complete information. Drug chart information is current as of February 1, 2019. Look up your drug by adding its name after you type positivelyaware.com/ into your browser (for example, positivelyaware.com/triumeq).



These medications contain a complete regimen all in one:

SINGLE TABLET REGIMENS (Mutliple drug classes; see pregnancy information for integrase inhibitors below.)



Atripla RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF)

One tablet (600 mg efavirenz/200 mg emtricitabine/300 mg tenofovir DF), once daily. Take on an empty stomach, preferably at bedtime.

One tablet (25 mg rilpivirine/200 mg emtricitabine/300 mg tenofovir DF),



Biktarvy * RECOMMENDED INITIAL REGIMEN

bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) One tablet (50 mg bictegravir/200 mg emtricitabine/25 mg tenofovir alafenamide), once daily. For adults who are treatment-naïve, or on treatment and virologically suppressed for at least 3 months, with no history of treatment failure or resistance mutations associated with components of Biktarvy. Take with or without food.

Delstrigo

RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS doravirine/lamivudine/tenofovir DF (DOR/3TC/TDF)

One tablet (100 mg doravirine/300 mg lamivudine/300 mg tenofovir DF), once daily. Take with or without food.

Juluca recommended as continuation therapy for people with undetectable hiv viral load for at least 6 months

One tablet (50 mg dolutegravir/25 mg rilpivirine), once daily. For adults who

are virologically suppressed on a current ART regimen for at least 6 months



once daily. Take with a meal.

Complera

RECOMMENDED INITIAL REGIMEN
IN CERTAIN CLINICAL SITUATIONS rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF)

Genvoya ✓ RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide

(EVG/COBI/FTC/TAF)

One tablet (150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/ 10 mg tenofovir alafenamide), once daily. Take with food.

rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF)

One tablet (25 mg rilpivirine/200 mg emtricitabine/25 mg tenofovir

Odefsey recommended initial regimen



and who have no history of treatment failure or resistance mutations associated with rilpivirine or dolutegravir. Take with a meal.

dolutegravir/rilpivirine (DTG/RPV)

Stribild

RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS elvitegravir/cobicistat/emtricitabine/tenofovir DF

(EVG/COBI/FTC/TDF) One tablet (150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/ 300 mg tenofovir DF), once daily. Take with food.



Symfi RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

alafenamide), once daily. Take with a meal.

efavirenz/lamivudine/tenofovir DF (EFV/3TC/TDF)

One tablet (600 mg efavirenz/300 mg lamivudine/300 mg tenofovir DF), once daily. Should be taken on an empty stomach, preferably at bedtime.



efavirenz/lamivudine/tenofovir DF (EFV/3TC/TDF)

One tablet (400 mg efavirenz/300 mg lamivudine/300 mg tenofovir DF), once daily. Should be taken on an empty stomach, preferably at bedtime.



Symtuza ✓ RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DRV/COBI/FTC/TAF)

One tablet (800 mg darunavir/150 mg cobicistat/200 mg emtricitabine/ 10 mg tenofovir alafenamide), once daily for patients without darunaviror tenofovir- related drug resistance. Take with food



Triumeq ★ RECOMMENDED INITIAL REGIMEN FOR MOST PEOPLE IF HLA-B*5701 NEGATIVE dolutegravir/abacavir/lamivudine (DTG/ABC/3TC)

One tablet (50 mg dolutegravir/600 mg abacavir/300 mg lamivudine), once daily. One additional 50 mg tablet of Tivicay 12 hours apart in people with viral resistance to INSTIs or when taken with certain other medications. Take with or without food.



dolutegravir/lamivudine

initial regimen to consider when ABC, TAF, AND TDF CANNOT BE USED OR ARE NOT OPTIMAL NOT YET APPROVED AT PRESS TIME.

One tablet, once daily. Tablet contains 50 mg of the INSTI dolutegravir plus 300 mg of the NRTI lamivudine. Lamivudine dosing needs to be adjusted for adults and children who have decreased kidney function (creatinine clearance less than 50 mL/min). Take with or without food.



LONG ACTING REGIMEN cabotegravir LA/rilpivirine LA ● DHHS RECOMMENDATION (CAB LA/RPV LA)

Long-acting injection of 400 mg cabotegravir plus 600 mg rilpivirine every

 $4\,\mbox{or}\,8$ weeks in studies. Dose in studies consisted of two 2 mL injections.



NOT YET APPROVED AT PRESS TIME.

Rilpivirine must be taken with food. Induction phase with oral medication used in research and will be used when approved. Cabotegravir lead-in dose tablet may not otherwise be available on the market.

These medications must be taken in combination with other HIV meds:

INTEGRASE INHIBITORS (Pregnancy testing should be performed in those of childbearing potential prior to initiation.)

PROTEASE INHIBITORS (Boosted and unboosted)



Isentress HD ★ RECOMMENDED AS COMPONENT OF INITIAL REGIMEN FOR MOST PEOPLE and Isentress

raltegravir (RAL) Isentress HD: Two 600 mg film-coated tablets, once daily. Isentress: One 400 mg film-coated tablet, twice daily.

Take with or without food



Tivicay ★ RECOMMENDED AS COMPONENT OF INITIAL REGIMEN FOR MOST PEOPLE

dolutegravir (DTG)

One 50 mg tablet, once daily for people on HIV therapy for the first time or treatment-experienced without previous INSTI resistance. Twice-daily dosing for people who have viral resistance to INSTIs or when taken with certain other medications. Take with or without food



Evotaz recommended as component of initial regimen in certain clinical situations

atazanavir/cobicistat (ATV/COBI) One tablet (300 mg atazanavir/150 mg cobicistat), once daily.



darunavir/cobicistat (DRV/COBI) One tablet (800 mg darunavir/150 mg cobicistat), once daily

Prezcobix ✓ RECOMMENDED AS COMPONENT OF INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

in patients with no darunavir drug resistance. Take with food.



Prezista ✓ RECOMMENDED AS COMPONENT OF INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

One 800 mg tablet with 100 mg Norvir or 150 mg Tybost, once daily for first-time therapy and treatment-experienced adults without Prezistarelated resistance; or one 600 mg tablet plus 100 mg Norvir, twice daily for treatment-experienced people with Prezista-related resistance. Prezista must be taken with Norvir or Tybost. Take with food.



Reyataz Precommended as component of initial regimen in certain clinical situations

atazanavir sulfate (ATV)

One 300 mg capsule plus 100 mg Norvir or 150 mg Tybost, once daily; or two 200 mg capsules (without boosting), once daily for treatment-naïve adults (see the POSITIVELY AWARE HIV Drug Guide for details). Take with food. GENERIC IS AVAILABLE.



Tybost

USED ONLY AS A BOOSTER FOR OTHER DRUGS;
RECOMMENDED AS COMPONENT OF INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

Used only for boosting—not an antiretroviral. 150 mg once daily taken at the same time with either Prezista 800 mg or Reyataz 300 mg. Take with food.



USED ONLY AS A BOOSTER FOR OTHER DRUGS; RECOMMENDED AS COMPONENT OF INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

Used only for boosting, also an antiretroviral. 100–200 mg, dosed once or twice daily with another PI. Must be taken with food. GENERIC IS AVAILABLE.



NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ("Nukes") ★ All "nukes" are recommended.

RECOMMENDED FOR INITIAL ART FOR MOST PERSONS WHEN COMBINED WITH TIVICAY OR ISENTRESS

lamivudine/tenofovir DF (3TC/TDF)

One 200 mg capsule, once daily. Take with or without food.



RECOMMENDED AS A COMPONENT OF INITIAL REGIMEN FOR MOST PEOPLE emtricitabine/tenofovir alafenamide (FTC/TAF)

One tablet (300 mg lamivudine/300 mg tenofovir DF), once daily, One tablet (200 mg emtricitabine/25 mg tenofovir alafenamide), taken in combination with other ARVs. Take with or without food. once daily. Take with or without food.





RECOMMENDED AS COMPONENT OF INITIAL REGIMEN FOR MOST PEOPLE WHEN USED IN COMBINATION WITH DOLUTEGRAVIR AND ABACAVIR

lamivudine (3TC) One 300 mg tablet, once daily; or one 150 mg tablet, twice daily. Take with or without food.



RECOMMENDED AS COMPONENT OF INITIAL REGIMEN FOR MOST PEOPLE IF HLA-B*5701-NEGATIVE WHEN USED IN COMBINATION WITH DOLUTEGRAVIR (AS TRIUMEQ)

abacavir/lamivudine (ABC/3TC)

One tablet (600 mg abacavir/300 mg lamivudine), once daily.



recommended as a component of initial regimen for most people

emtricitabine/tenofovir DF (FTC/TDF)

GENERIC IS AVAILABLE

GENERIC IS AVAILABLE.

efavirenz (EFV)

GENERIC IS AVAILABLE.

at bedtime.



One tablet (200 mg emtricitabine/300 mg tenofovir DF), once daily. Take with or without food. APPROVED AS GENERIC, WHICH IS NOT YET COMMERCIALLY AVAILABLE.



RECOMMENDED AS COMPONENT OF INITIAL REGIMEN FOR MOST PEOPLE IF HLA-B*5701-NEGATIVE WHEN USED IN COMBINATION WITH DOLUTEGRAVIR AND LAMIVUDINE (AS TRIUMEQ)



abacavir sulfate (ABC)

Two 300 mg tablets, once daily; or one 300 mg tablet, twice daily. Take with or without food.



tenofovir disoproxil fumarate (TDF) One 300 mg tablet, once daily. Take with or without food. GENERIC IS AVAILABLE.

Viread RECOMMENDED AS A COMPONENT OF INITIAL REGIMEN FOR MOST PEOPLE

NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (Non nukes" Edurant

RECOMMENDED AS COMPONENT OF INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS IN COMBINATION WITH DESCOVY OR TRUVADA (AS ODEFSEY OR COMPLERA)

Take with or without food.

GENERIC IS AVAILABLE.

rilpivirine (RPV)

doravirine (DOR)



Intelence

FOR TREATMENT-EXPERIENCED PATIENTS
WITH VIRAL STRAINS RESISTANT TO AN NNRTI
AND OTHER ANTIRETROVIRAL DRUGS ONLY



One 25 mg tablet, once daily. Take with a meal.

RECOMMENDED AS COMPONENT OF INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS IN COMBINATION WITH DESCOVY OR TRUVADA, OR WITH CIMDUO (AS DELSTRIGO)

One 100 mg tablet, once daily. Take with or without food.



etravirine (FTR) One 200 mg tablet, twice daily. Take with food.



Sustiva

RECOMMENDED AS COMPONENT OF INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS (AS A PART OF ATRIPLA, SYMFI, AND SYMFILO, OR WITH DESCOVY OR TRUVADA)

One 600 mg tablet, once daily. Take on an empty stomach, preferably



Selzentry maraviroc (MVC) NOT RECOMMENDED AS

COMPONENT OF AN INITIAL REGIMEN ENTRY INHIBITOR: CCR5 ANTAGONIST

150, 300, or 600 mg (available in 150 and 300 mg tablets), twice daily, depends on other medications used (see the POSITIVELY AWARE HIV Drug Guide for details). Take with or without food.



ibalizumab-uiyk (IBA) FOR PEOPLE LACKING SUFFICIENT TREATMENT OPTIONS

ENTRY/ATTACHMENT INHIBITORS

CD4 POST-ATTACHMENT INHIBITOR

Administered once every two weeks via intravenous infusion. Treatment begins with an IV loading (starting) dose

of 2,000 mg, followed by an 800 mg

IV infusion maintenance dose given

every two weeks thereafter.



fostemsavir

DHHS RECOMMENDATION NOT YET ESTABLISHED

ATTACHMENT INHIBITOR

antiretroviral resistance.

NOT YET APPROVED AT PRESS TIME. In clinical trials, the investigational dose taken forward for further study was 600 mg, sometimes once daily and sometimes twice daily. Doses were taken after eating. For highly-treatment experienced individuals with history of

LEGACY DRUGS The following drugs are no longer or rarely prescribed:



Combivir lamivudine/zidovudine (3TC/AZT)

Crixivan indinavir (IDV)

abacavir/lamivudine/

zidovudine (ABC/3TC/AZT)





SOV 500

Kaletra lopinavir/ritonavir (LPV/r)

Lexiva fosamprenavir calcium (FPV)





zidovudine (AZT, or ZDV)





didanosine (ddl)



Viramune XR nevirapine (NVP)

Zerit

stavudine (d4T)

